Otsuka Presents Final Phase 3 VISIONARY Results at ASN Demonstrating Sibeprenlimab Stabilised Kidney Function and Reduced Risk of Disease Progression and Kidney Failure in IgA Nephropathy
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY
Otsuka Presents Final Phase 3 VISIONARY Results at ASN Demonstrating Sibeprenlimab Stabilised Kidney Function and Reduced Risk of Disease Progression and Kidney Failure in IgA Nephropathy
Results from the Phase 3 VISIONARY trial showed a 97% reduction in the risk of a composite kidney outcom